Orphan drug designation and pharmacogenomics: Options and opportunities

BioDrugs

Volumn 20, Issue 2, 2006, Pages 71-79

  Maher, Paul D ^a   Haffner, Marlene ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AGALSIDASE BETA; ALEMTUZUMAB; ALPHA 1 ANTITRYPSIN; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BASILIXIMAB; BETA1A INTERFERON; DACLIZUMAB; DENILEUKIN DIFTITOX; DORNASE ALFA; FOMIVIRSEN; GALACTOSE; GAMMA1B INTERFERON; GEMTUZUMAB OZOGAMICIN; HUMAN GROWTH HORMONE; IBRITUMOMAB TIUXETAN; IMATINIB; IMIGLUCERASE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 2 RECEPTOR GAMMA; LARONIDASE; MACROGOL; MONOCLONAL ANTIBODY; NITISINONE; ORPHAN DRUG; PARVOVIRUS VECTOR; PEGADEMASE; RASBURICASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT LUTEINIZING HORMONE; RETROVIRUS VECTOR; RITUXIMAB; SMALL INTERFERING RNA; THALIDOMIDE; TOSITUMOMAB I 131; TRASTUZUMAB; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; CANCER; CHRONIC GRANULOMATOUS DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; DNA SEQUENCE; DRUG APPROVAL; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; ENZYME DEFICIENCY; FABRY DISEASE; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENE TRANSLOCATION; GENETIC DISORDER; HEALTH CARE; HUMAN; HUMAN GENOME; HURLER SYNDROME; IMMUNOGENICITY; INBORN ERROR OF METABOLISM; NONHUMAN; OSTEOPOROSIS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T CELL LEUKEMIA; TYROSINEMIA; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKED DISORDER;

EID: 33646237560     PISSN: 11738804     EISSN: 11738804     Source Type: Journal    
DOI: 10.2165/00063030-200620020-00001     Document Type: Review

References (49)

1. Orphan Drug Act, Pub. L. 97-414, Jan. 4, 1983, 96 Stat. 2049
2. Federal Food, Drug, and Cosmetic Act, June 25, 1938, ch. 675, 52 Stat. 1040 (21 USC 301 et seq.)
3. FDA Office of Orphan Products Development (OOPD). Internal OOPD database. Rockville (MD): FDA [online]. Available from URL: http://www.fda.gov/orphan/ [Accessed 2006 Mar 27]
4. Thoene JG. Orphan drugs and orphan tests in the USA. Community Genet 2004; 7: 169-72
5. Dockhorn RJ. Orphan drugs provide needed treatment options. Md Med 2005; 6 (1): 26-9
6. Hulton SA, Greener M. Increasing the use of orphan drugs in clinical practice. Hosp Med 2004; 65: 400-3
7. Grienenberger A. Understanding orphan drug regulations: an EU and US comparative analysis. J Biolaw Bus 2004; 7: 58-61
8. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [published erratum appears in Science 2001 Jun 5; 292 (5523): 1838]. Science 2001 Feb 16; 291 (5507): 1304-51
9. Collins FS, Green ED, Guttmacher AE, et al. A vision for the future of genomics research. Nature 2003 Apr 24; 422 (6934): 835-47
10. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348 (6): 538-49
11. Couzin J, Kaiser J. Gene therapy: as Gelsinger case ends, gene therapy suffers another blow. Science 2005 Feb 18; 307 (5712): 1028
12. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002 Apr 18; 346 (16): 1185-93
13. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003 Jan 16; 348 (3): 255-6
14. FDA Press Office. FDA places temporary halt on gene therapy trials using retroviral vectors in blood stem cells. FDA Talk Paper 2003 Jan 14. Rockville (MD): FDA [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01190.html [Accessed 2005 Dec 15]
15. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X. Science 2003 Oct 17; 302 (5644): 415-9
16. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004 Jan 16; 303 (5656): 333
17. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005; 5: 468-79
18. FDA. Consumer information: Vitravene [package insert]. Rockville (MD): FDA, 1998 Aug 26
19. FDA. Biotechnology of food. FDA Backgrounder 1994 May 18; BG 94-4 [online]. Available from URL: http://www.cfsan.fda.gov/∼lrd/biotechn.html [Accessed 2006 Feb 23]
20. Bantounas I, Phylactou LA, Uney JB. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 2004; 33: 545-57
21. Bidoul L, et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of read through efficiencies in response to gentamicin treatment. Gene Ther 2004; 11: 619-27
22. Stephenson J. Antibiotics show promise as therapy for genetic disorders. JAMA 2001; 285: 2067-8
23. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-41
24. Florian WM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22: 1393-8
25. Bory C, Boulieu R, Souillet G, et al. Polyethylene glycol-adenosine deaminase: a new adenosine deaminase deficiency therapy. Value of deoxyadenosine triphosphate determination for therapeutic monitoring [in French] [published erratum appears in Therapie 1991 Nov-Dec;46 (6): 501]. Therapie 1991 Jul-Aug; 46 (4): 323-6
26. Chaffee S, Hersfield, MS. Imuune response to polyethylene glycol modified bovine adenosine deaminase (PEG-ADA). Pediatr Res 1990; 27 (4 Pt 2): 155A
27. OOPD. Grant no. FDR-000285-01 to Abuchowski A. Severe combined immunogenicity disease: enzyme therapy. Rockville (MD): FDA [online]. Available from http://www.fda.gov/orphan/grants/previous.htm [Accessed 2006 Mar 28]
28. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 2001 Nov; 21 (4): 563-71
29. Neergaard L. FDA OKs drug to fight liver disease. Associated Press, 2002 Jan 23 [online]. Available from URL: http://www.communities.ninemsn.com/tyrosinemia/ntbc.msnw [Accessed 2006 Feb 23]
30. de Geus B, Hendriksen CFM. In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Res Immunol 1998 Jul-Aug; 149 (6): 542-7
31. FDA News. FDA approves Gleevec for leukemia treatment. Rockville (MD): FDA, 2001 May 10
32. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031-7
33. FDA Press Office. FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution. FDA Talk Paper, 1998 Jul 16. Rockville (MD): FDA [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS00887.html [Accessed 2005 Dec 15]
34. FDA. Consumer information: Herceptin® (Trastuzumab) [package insert]. Rockville (MD): FDA [online]. Available from URL: http://www.fda.gov/cder/foi/label/2000/trasgen020900lb.pdf [Accessed 2006 Mar 28]
35. Hochaus A, Highes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004 Jun; 18 (3): 641-56, ix
36. Chuang DT. Maple syrup urine disease: it has come a long way. J Pediatr 1998 Mar; 132 (3 Pt 2): S17-23
37. Chuang DT, Shih VE. Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. Vol. II. 8th ed. New York: McGraw-Hill, 2001: 1971-2005
38. Patel MS, Harris RA. Mammalian alpha-keto acid dehydrogenase complexes: gene regulation and genetic defects. FASEB J 1995; 9: 1164-72
39. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur J Cancer 2005 May; 41 (8): 1109-16
40. Sieper J, Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum 2005 Apr; 34 (5 Suppl. 1): 23-7
41. Breunig F, Weidemann F, Beer M, et al. Fabry disease: diagnosis and treatment. Kidney Int Suppl 2003; 63 (84): S181-5
42. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose infusion therapy. N Engl J Med 2001; 345: 25-32
43. Gahl WA. New therapies for Fabry's disease. N Engl J Med 2001 Jul 5; 345 (1): 55-7
44. Garman SC, Garboczi DN. Minireview: structural basis of Fabry disease. Mol Genet Metab 2002; 77: 3-11
45. Helenius A, Marquardt T, Braakman I. The endoplasmic reticulum as a protein folding compartment. Trends Cell Biol 1992; 2: 227-31
46. Fan JQ. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003; 24: 356-36
47. Clinical Laboratory Improvement Amendments, Pub. L 100-578, 1988, ch. 6A [Public Health Service Act] (42 USC 263a)
48. Clinical Laboratory Improvement Amendments Regulations, 42 CFR 493
49. Chiche JD, Cariou A, Mira JP. Bench-to-bedside review: fulfilling promises of the Human Genome Project. Crit Care 2002; 6 (3): 212-5